SCHEMBL2284208

SCHEMBL2284208

CCCC(O)N1CCOCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
LMNA P02545 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
RAB9A P51151 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
USP2 O75604 1/20 0.40
TSHR P16473 2/20 0.39
KCNA5 P22460 2/20 0.35
KCNH2 Q12809 2/20 0.35
HTT P42858 2/20 0.34
POLB P06746 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MEN1 O00255 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
RECQL P46063 1/20 0.32
CTSS P25774 1/20 0.31
FAAH O00519 1/20 0.31
PHGDH O43175 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20863035 0.88 KCNH2 (0.42) ALDH1A1LMNAKMT2AMAPTHPGD
SCHEMBL11743635 0.86 KCNA5 (0.42) ALDH1A1LMNAKMT2AMAPTHPGD
SCHEMBL27588961 0.84 KCNA5 (0.44) ALDH1A1LMNAKMT2AMAPTHPGD
SCHEMBL8972603 0.84 KCNA5 (0.44) ALDH1A1LMNAKMT2AMAPTHPGD
SCHEMBL27269583 0.84
SCHEMBL3176857 0.82 ALDH1A1 (0.47) ALDH1A1LMNAKMT2AMAPTHPGD
SCHEMBL5980403 0.80 USP2 (0.41) ALDH1A1LMNAKMT2AMAPTHPGD
Hydrochloric Acid SCHEMBL516841 0.80 ALDH1A1 (0.46) ALDH1A1LMNAKMT2AMAPTHPGD
SCHEMBL3248168 0.79 SLC6A3 (0.41)
SCHEMBL9738640 0.77 KMT2A (0.39) ALDH1A1LMNAKMT2AMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030327-B2 3-[1-(2-chlorophenyl)ethoxy]-5-imidazo[1,2-a]pyridin-3-ylthiophene-2-carboxyamide; polo like kinase inhibitor; antitumor and anticarcinogenic agent; mitotic phase (M phase) of the cell cycle MDS K.K. (JP) 2011-10-04 US disclosed
US-7998949-B2 Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-08-16 US disclosed
EP-1702960-B1 Pigment dispersing agent, pigment composition and pigment dispersion TOYO INK MFG CO (JP) 2010-05-12 EP disclosed
US-20080103136-A1 Novel Fused Imidazole Derivative MSD K.K. (JP) 2008-05-01 US disclosed
US-7147704-B2 Pigment dispersing agent, pigment composition and pigment dispersion TOKYO INK MFG. CO., LTD (JP) 2006-12-12 US disclosed
US-20060207478-A1 Dispersant has a quinophthalone structure bonded to a triazine structure through an arylene or a heteroaromatic ring and having a basic functional group bonded to the triazine ring through a connecting group; improved fluidity; improved tinting strength, transparency and viscosity stability TOYO INK MFG. CO., LTD. (JP) 2006-09-21 US disclosed
EP-1702960-A2 Pigment dispersing agent, pigment composition and pigment dispersion TOYO INK MFG. CO., LTD. (JP) 2006-09-20 EP disclosed
EP-1022273-B1 Pigment composition containing a pigment dispersing agent TOYO INK MFG CO (JP) 2004-07-14 EP disclosed
EP-0955275-B1 Coating composition for coloring a glass, process for the preparation thereof and use thereof TOYO INK MFG CO (JP) 2002-06-26 EP disclosed
US-6333371-B1 Coating composition for coloring a glass, process for the production thereof and use thereof TOYO INK MFG. CO., LTD. (JP) 2001-12-25 US disclosed
EP-1052230-A1 Coating composition for coloring glass TOYO INK MANUFACTURING CO., LTD. (JP) 2000-11-15 EP disclosed
US-6123763-A PROVIDES AN INK OR A COATING COMPOSITIONFREEDOM OF AGGREGATION, NON-CRYSTALLIZABILITY AND FLUIDITY, TOYO INK MFG. CO., LTD. (JP) 2000-09-26 US disclosed
EP-0710706-B1 Method for dispersing pigment and water-based pigment dispersion TOYO INK MFG CO (JP) 2000-09-06 EP disclosed
EP-1022273-A1 Pigment dispersing agent and pigment composition containing the same TOYO INK MANUFACTURING CO., LTD. (JP) 2000-07-26 EP disclosed
EP-0955275-A1 Coating composition for coloring a glass, process for the preparation thereof and use thereof TOYO INK MANUFACTURING CO., LTD. (JP) 1999-11-10 EP disclosed
US-5635552-A MIXTURES OF PIGMENT, DISPERSANT, WATER-BASED RESIN AND WATER SOLUBLE SOLVENT, FOR COATINGS, INKS TOYO INK MANUFACTURING CO., LTD. (JP) 1997-06-03 US disclosed
EP-0710706-A2 Method for dispersing pigment and water-based pigment dispersion TOYO INK MANUFACTURING CO., LTD. (JP) 1996-05-08 EP disclosed
US-5476544-A Dispersing agent TOYO INK MANUFACTURING CO., LTD. (JP) 1995-12-19 US disclosed
US-4664714-A TRIAZINE-CONTAINING DISPERSANT TOYO INK MANUFACTURING CO., LTD. (JP) 1987-05-12 US disclosed
US-4005085-A SEDATIVES, ANTI-CONVULSANTS, MUSCLE RELAXANTS AND ANXIOLYTIC ACTIVITIES HOFFMANN-LA ROCHE INC. (US) 1977-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103136-A1 Novel Fused Imidazole Derivative HRH4, H1-4, H1-3 ALDH1A1 1939/4885LMNA 3610/4885KMT2A 1819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.